By using syngeneic tumor models, we confirmed that the combinatory treatment of pemetrexed (without cisplatin) with PD-1/PD-L1 blockage antibodies is sufficient to inhibit tumor growth through the activation and/or recruitment of tumor-infiltrating CD4 and CD8 T-lymphocytes. The gene discussed is CD4; the disease is neoplasm.